Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Intangibles (2023 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Intangibles for 4 consecutive years, with $93.9 million as the latest value for Q1 2026.

  • For Q1 2026, Intangibles fell 37.65% year-over-year to $93.9 million; the TTM value through Mar 2026 reached $93.9 million, down 37.65%, while the annual FY2025 figure was $93.9 million, 37.65% down from the prior year.
  • Intangibles hit $93.9 million in Q1 2026 for Cartesian Therapeutics, roughly flat from $93.9 million in the prior quarter.
  • Across five years, Intangibles topped out at $150.6 million in Q4 2023 and bottomed at $93.9 million in Q4 2025.
  • Average Intangibles over 4 years is $139.3 million, with a median of $150.6 million recorded in 2023.
  • Year-over-year, Intangibles changed 0.0% in 2024 and then tumbled 37.65% in 2025.
  • Cartesian Therapeutics' Intangibles stood at $150.6 million in 2023, then changed by 0.0% to $150.6 million in 2024, then crashed by 37.65% to $93.9 million in 2025, then changed by 0.0% to $93.9 million in 2026.
  • According to Business Quant data, Intangibles over the past three periods came in at $93.9 million, $93.9 million, and $150.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.